YourRad AB is Providing MVision’s AI-Powered Segmentation Service to Nordic Cancer Hospitals

Helsinki – 5th of November, 2021 – MVision AI, the pioneer of SaaS radiotherapy treatment planning optimization, announces their distribution partnership YourRad AB, the prime supplier of radiation treatment products for Nordic Clinics.

The commitment authorizes YourRad AB with the entitlement to distribute products and services of MVision AI in the Nordic region. YourRad AB and MVision AI are devoted to accelerated, prime, and guideline-based provisions of radiotherapy solutions for Nordic radiation oncology practices. The MVision AI team will collaborate with YourRad staff to assure the dispensation of superior, swift, and dependable radiotherapy services.

“We are happy and proud of the partnership with MVISION Oy. The feedback from our end users in radiotherapy have been excellent. It mainly highlights the fact that the quality and consistency are excellent and that the value for both health care professionals and patients is great. Very high quality in delineating OAR´s and time saving are the key benefits according to customers,” says M. Forss, CEO of YourRad AB. 

As stated by Mahmudul Hasan, CEO, and co-founder of MVision AI, “MVision is delighted to partner with YourRad AB to bring our guideline-based AI segmentation (GBAIS™ and GCAIS™) to Nordic customers. Nordic countries have always been at the forefront of adopting cutting-edge technologies. MVision is excited to bring more innovative solutions to facilitate same-day treatment as a reality.”

For additional information on YourRad AB:

Magasinsgatan 8C, 434 37, Kungsbacka, Sweden

Tel: +46 (0) 70 609 88 91 

Email: info@yourrad.se

LinkedIn: https://www.linkedin.com/company/yourrad-ab/?originalSubdomain=se 

For supplementary information on MVision AI: 

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@mvision.ai 

Social Media: Facebook, Instagram, LinkedIn, Twitter, and Youtube

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

 

Previous Post
The Current State of Cancer Care and Radiotherapy in the US
Next Post
Examining the Capacity of Radiotherapy to Treat Lung Cancer
Sign up for newsletter

    Menu